# Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy

> **NCT06998108** · PHASE3 · RECRUITING · sponsor: **BeBetter Med Inc** · enrollment: 330 (estimated)

## Conditions studied

- HR+/HER2- Locally Advanced, Metastatic Breast Cancer

## Interventions

- **DRUG:** BEBT-209 capsules
- **DRUG:** BEBT-209 Placebo capluses
- **DRUG:** Fulvestrant Injection

## Key facts

- **NCT ID:** NCT06998108
- **Lead sponsor:** BeBetter Med Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-09
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2025-05-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06998108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06998108, "Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT06998108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*